Advances in the pharmacological treatment of Parkinson's disease: Targeting neurotransmitter systems

Trends in Neurosciences

Volumn 36, Issue 9, 2013, Pages 543-554

  Brichta, Lars ^a   Greengard, Paul ^a   Flajolet, Marc ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Acetylcholine; Basal ganglia; Dopamine; GABA; Glutamate; Norepinephrine; Parkinson's disease; Serotonin; Striatum; Substantia nigra

Indexed keywords

AMANTADINE; APOMORPHINE; BF 2649; CAFFEINE; CARBIDOPA PLUS LEVODOPA; CREATINE; DEFERIPRONE; DONEPEZIL; ESZOPICLONE; GALANTAMINE; ISTRADEFYLLINE; KW 6500; LISURIDE; NALOXONE PLUS OXYCODONE; NEUROTRANSMITTER; NEUROTRANSMITTER RECEPTOR; NEUROTRANSMITTER TRANSPORTER; OPICAPONE; PAROXETINE; PIMAVANSERIN; PITOLISANT; PRAMIPEXOLE; PRELADENANT; RASAGILINE; RIVASTIGMINE; ROPINIROLE; ROTIGOTINE; S ADENOSYLMETHIONINE; SAFINAMIDE; TOZADENANT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE;

CHOLINERGIC SYSTEM; CLINICAL TRIAL (TOPIC); DOPAMINERGIC SYSTEM; DRUG TARGETING; GABAERGIC SYSTEM; HUMAN; NEUROMODULATION; NORADRENERGIC SYSTEM; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC SYSTEM;

ACETYLCHOLINE; BASAL GANGLIA; DOPAMINE; GABA; GLUTAMATE; NOREPINEPHRINE; PARKINSON'S DISEASE; SEROTONIN; STRIATUM; SUBSTANTIA NIGRA;

ANIMALS; ANTIPARKINSON AGENTS; HUMANS; NEUROTRANSMITTER AGENTS; PARKINSON DISEASE;

EID: 84883828888     PISSN: 01662236     EISSN: 1878108X     Source Type: Journal    
DOI: 10.1016/j.tins.2013.06.003     Document Type: Review

References (94)

1. Chaudhuri K.R., Schapira A.H. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009, 8:464-474.
2. Chaudhuri K.R., et al. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 2006, 5:235-245.
3. Langston J.W. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann. Neurol. 2006, 59:591-596.
4. Hely M.A., et al. Sydney Multicenter Study of Parkinson's disease: non-L-Dopa-responsive problems dominate at 15 years. Mov. Disord. 2005, 20:190-199.
5. Schrag A., et al. What contributes to quality of life in patients with Parkinson's disease?. J. Neurol. Neurosurg. Psychiatry 2000, 69:308-312.
6. Factors impacting on quality of life in Parkinson's disease: results from an international survey. Mov. Disord. 2002, 17:60-67. Global Parkinson's Disease Survey Steering Committee.
7. Fahn S. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs later L-DOPA. Arch. Neurol. 1999, 56:529-535.
8. Rascol O., et al. N. Engl. J. Med. 2000, 342:1484-1491. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group.
9. Rascol O., et al. Development of dyskinesias in a 5-year trial of ropinirole and L-Dopa. Mov. Disord. 2006, 21:1844-1850.
10. Stocchi F., et al. A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients. Mov. Disord. 2012, 27:106-112.
11. Pevarello P., et al. Synthesis and anticonvulsant activity of a new class of 2-[(arylalky)amino]alkanamide derivatives. J. Med. Chem. 1998, 41:579-590.
12. Emre M., et al. Rivastigmine for dementia associated with Parkinson's disease. N. Engl. J. Med. 2004, 351:2509-2518.
13. Litvinenko I.V., et al. Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial). Neurosci. Behav. Physiol. 2008, 38:937-945.
14. Ravina B., et al. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J. Neurol. Neurosurg. Psychiatry 2005, 76:934-939.
15. Leroi I., et al. Randomized controlled trial of memantine in dementia associated with Parkinson's disease. Mov. Disord. 2009, 24:1217-1221.
16. Aarsland D., et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009, 8:613-618.
17. Emre M., et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010, 9:969-977.
18. Seppi K., et al. The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the non-motor symptoms of Parkinson's disease. Mov. Disord. 2011, 26(Suppl. 3):S42-S80.
19. Rajput A.H., et al. Globus pallidus dopamine and Parkinson motor subtypes: clinical and brain biochemical correlation. Neurology 2008, 70:1403-1410.
20. Beaulieu J.M., Gainetdinov R.R. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol. Rev. 2011, 63:182-217.
21. Missale C., et al. Dopamine receptors: from structure to function. Physiol. Rev. 1998, 78:189-225.
22. 11C]-(+)-PHNO in drug-naive Parkinson's disease. Brain 2009, 132:1366-1375.
23. Mierau J., et al. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur. J. Pharmacol. 1995, 290:29-36.
24. Barone P., et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010, 9:573-580.
25. Sun J., et al. Dopamine D1, D2, D3 receptors, vesicular monoamine transporter type-2 (VMAT2) and dopamine transporter (DAT) densities in aged human brain. PLoS ONE 2012, 7:e49483.
26. 11C-FLB 457. PLoS ONE 2011, 6:e17723.
27. Pahwa R., et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 2007, 68:1108-1115.
28. 1 dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates. Neurobiol. Dis. 2007, 26:452-463.
29. Aubert I., et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann. Neurol. 2005, 57:17-26.
30. Guttman M., et al. Brain serotonin transporter binding in non-depressed patients with Parkinson's disease. Eur. J. Neurol. 2007, 14:523-528.
31. Albin R.L., et al. Spared caudal brainstem SERT binding in early Parkinson's disease. J. Cereb. Blood Flow Metab. 2008, 28:441-444.
32. Kish S.J., et al. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain 2008, 131:120-131.
33. Burn D.J. Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson's disease. Mov. Disord. 2002, 17:445-454.
34. Aarsland D., et al. Depression in Parkinson disease - epidemiology, mechanisms and management. Nat. Rev. Neurol. 2012, 8:35-47.
35. Richard I.H., et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 2012, 78:1229-1236.
36. Remy P., et al. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005, 128:1314-1322.
37. Menza M., et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009, 72:886-892.
38. Devos D., et al. Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov. Disord. 2008, 23:850-857.
39. 2A receptor inverse agonist, for the treatment of Parkinson's disease psychosis. Neuropsychopharmacology 2010, 35:881-892.
40. Navailles S., De Deurwaerdere P. Presynaptic control of serotonin on striatal dopamine function. Psychopharmacology (Berl.) 2011, 213:213-242.
41. Huot P., et al. The serotonergic system in Parkinson's disease. Prog. Neurobiol. 2011, 95:163-212.
42. Barnes N.M., Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999, 38:1083-1152.
43. Ballanger B., et al. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch. Neurol. 2010, 67:416-421.
44. Huot P., et al. Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations. Mov. Disord. 2010, 25:1399-1408.
45. Huot P., et al. Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism?. J. Pharmacol. Exp. Ther. 2011, 339:2-8.
46. Grimbergen Y.A., et al. Postural instability in Parkinson's disease: the adrenergic hypothesis and the locus coeruleus. Expert Rev. Neurother. 2009, 9:279-290.
47. Moreau C., et al. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurol. 2012, 11:589-596.
48. Palacios J.M., et al. α1-Adrenoceptors in the mammalian brain: similar pharmacology but different distribution in rodents and primates. Brain Res. 1987, 419:65-75.
49. Pascual J., et al. Quantitative light microscopic autoradiographic localization of α2-adrenoceptors in the human brain. Brain Res. 1992, 585:116-127.
50. Joyce J.N., et al. Distribution of beta-adrenergic receptor subtypes in human postmortem brain: alterations in limbic regions of schizophrenics. Synapse 1992, 10:228-246.
51. Russo-Neustadt A., Cotman C.W. Adrenergic receptors in Alzheimer's disease brain: selective increases in the cerebella of aggressive patients. J. Neurosci. 1997, 17:5573-5580.
52. Rodriguez M., et al. Evidence for the presence of β3-adrenergic receptor mRNA in the human brain. Brain Res. Mol. Brain Res. 1995, 29:369-375.
53. Lewitt P.A., et al. Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study). Neurology 2012, 79:163-169.
54. Greengard P. The neurobiology of slow synaptic transmission. Science 2001, 294:1024-1030.
55. Niswender C.M., Conn P.J. Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu. Rev. Pharmacol. Toxicol. 2010, 50:295-322.
56. Calon F., et al. Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol. Dis. 2003, 14:404-416.
57. Ouattara B., et al. Metabotropic glutamate receptor type 5 in levodopa-induced motor complications. Neurobiol. Aging 2011, 32:1286-1295.
58. Ahmed I., et al. Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias. Brain 2011, 134:979-986.
59. Anon. (2002) Amantadine and other antiglutamate agents: management of Parkinson's disease. Mov Disord 17 (Suppl. 4), S13-S22.
60. Matsubayashi H., et al. Amantadine inhibits nicotinic acetylcholine receptor function in hippocampal neurons. J. Pharmacol. Exp. Ther. 1997, 281:834-844.
61. Nutt J.G., et al. Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism. Mov. Disord. 2008, 23:1860-1866.
62. Karachi C., et al. Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease. J. Clin. Invest. 2010, 120:2745-2754.
63. Berg D., et al. AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov. Disord. 2011, 26:1243-1250.
64. Duty S. Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease. CNS Drugs 2012, 26:1017-1032.
65. Gerfen C.R., Surmeier D.J. Modulation of striatal projection systems by dopamine. Annu. Rev. Neurosci. 2011, 34:441-466.
66. Calon F., et al. Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications. Mov. Disord. 2003, 18:241-253.
67. McNeill T.H., et al. Atrophy of medium spiny I striatal dendrites in advanced Parkinson's disease. Brain Res. 1988, 455:148-152.
68. Stephens B., et al. Evidence of a breakdown of corticostriatal connections in Parkinson's disease. Neuroscience 2005, 132:741-754.
69. Day M., et al. Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat. Neurosci. 2006, 9:251-259.
70. Quik M., Wonnacott S. α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease. Pharmacol. Rev. 2011, 63:938-966.
71. Ferreira J.J., et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur. J. Neurol. 2013, 20:5-15.
72. Ding J., et al. RGS4-dependent attenuation of M4 autoreceptor function in striatal cholinergic interneurons following dopamine depletion. Nat. Neurosci. 2006, 9:832-842.
73. Rinne J.O., et al. Loss of cholinergic neurons in the pedunculopontine nucleus in Parkinson's disease is related to disability of the patients. Parkinsonism Relat. Disord. 2008, 14:553-557.
74. Moro E., et al. Unilateral pedunculopontine stimulation improves falls in Parkinson's disease. Brain 2010, 133:215-224.
75. Ferraye M.U., et al. Effects of pedunculopontine nucleus area stimulation on gait disorders in Parkinson's disease. Brain 2010, 133:205-214.
76. Paterson D., Nordberg A. Neuronal nicotinic receptors in the human brain. Prog. Neurobiol. 2000, 61:75-111.
77. Grinevich V.P., et al. Heterologous expression of human α6β4β3α5 nicotinic acetylcholine receptors: binding properties consistent with their natural expression require quaternary subunit assembly including the α5 subunit. J. Pharmacol. Exp. Ther. 2005, 312:619-626.
78. Goldberg J.A., et al. Muscarinic modulation of striatal function and circuitry. Handb. Exp. Pharmacol. 2012, 208:223-241.
79. Reever C.M., et al. The M5 (m5) receptor subtype: fact or fiction?. Life Sci. 1997, 60:1105-1112.
80. Canals M., et al. Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J. Biol. Chem. 2003, 278:46741-46749.
81. 2A adenosine receptor antagonists in the therapy of Parkinson's disease. Pharmacol. Ther. 2011, 132:280-299.
82. Mizuno Y., Kondo T. Adenosine A receptor antagonist istradefylline reduces daily off time in Parkinson's disease. Mov. Disord. 2013, 10.1002/mds.25418.
83. Mizuno Y., et al. Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study. Mov. Disord. 2010, 25:1437-1443.
84. Hauser R.A., et al. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Mov. Disord. 2008, 23:2177-2185.
85. Stacy M., et al. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology 2008, 70:2233-2240.
86. LeWitt P.A., et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces 'off' time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann. Neurol. 2008, 63:295-302.
87. Ramlackhansingh A.F., et al. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease. Neurology 2011, 76:1811-1816.
88. 2A receptors measured with [C]TMSX PET in the striata of Parkinson's disease patients. PLoS ONE 2011, 6:e17338.
89. Pisani V., et al. Homeostatic changes of the endocannabinoid system in Parkinson's disease. Mov. Disord. 2011, 26:216-222.
90. Kreitzer A.C., Malenka R.C. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 2007, 445:643-647.
91. Yin H.H., Lovinger D.M. Frequency-specific and D2 receptor-mediated inhibition of glutamate release by retrograde endocannabinoid signaling. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:8251-8256.
92. Marti M., et al. The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA. J. Neurochem. 2008, 107:1683-1696.
93. Visanji N.P., et al. The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov. Disord. 2008, 23:1922-1925.
94. 2A receptor to regulate synaptic plasticity. Nat. Neurosci. 2008, 11:1402-1409.